These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 20516563

  • 1. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW.
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [Abstract] [Full Text] [Related]

  • 2. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N, Bansi-Matharu L, Churchill D, Dunn D, Bibby D, Hill T, Sabin C, Nelson M, UK Collaborative HIV Cohort (CHIC) Study Group, UK HIV Drug Resistance Database (UK HDRD) Study Group.
    J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
    [Abstract] [Full Text] [Related]

  • 3. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM, Lee TS, Ross L, Lloyd RM, Lewinski MA, Potts SJ.
    Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
    [Abstract] [Full Text] [Related]

  • 4. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM, Sabin C, Forbici F, Bansi L, Dunn D, Fearnhill E, Boumis E, Nicastri E, Antinori A, Palamara G, Callegaro A, Francisci D, Zoncada A, Maggiolo F, Zazzi M, Perno CF, Ceccherini-Silberstein F, Mussini C.
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [Abstract] [Full Text] [Related]

  • 5. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity.
    White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK.
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3437-46. PubMed ID: 12384348
    [Abstract] [Full Text] [Related]

  • 6. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.
    Ly JK, Margot NA, MacArthur HL, Hung M, Miller MD, White KL.
    Antivir Chem Chemother; 2007 Nov; 18(6):307-16. PubMed ID: 18320935
    [Abstract] [Full Text] [Related]

  • 7. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.
    AIDS; 1998 May 07; 12(7):705-12. PubMed ID: 9619801
    [Abstract] [Full Text] [Related]

  • 8. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
    Delaunay C, Brun-Vézinet F, Landman R, Collin G, Peytavin G, Trylesinski A, Flandre P, Miller M, Descamps D.
    J Virol; 2005 Aug 07; 79(15):9572-8. PubMed ID: 16014919
    [Abstract] [Full Text] [Related]

  • 9. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.
    AIDS; 2003 Sep 05; 17(13):1889-96. PubMed ID: 12960821
    [Abstract] [Full Text] [Related]

  • 10. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
    Ross LL, Rouse E, Gerondelis P, DeJesus E, Cohen C, Horton J, Ha B, Lanier ER, Elion R, COL40263 study.
    J Antimicrob Chemother; 2010 Feb 05; 65(2):307-15. PubMed ID: 20008905
    [Abstract] [Full Text] [Related]

  • 11. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
    Descamps D, Ait-Khaled M, Craig C, Delarue S, Damond F, Collin G, Brun-Vézinet F.
    Antivir Ther; 2006 Feb 05; 11(6):701-5. PubMed ID: 17310814
    [Abstract] [Full Text] [Related]

  • 12. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B, Neau D, Boucher S, Lavignolle-Aurillac V, Schrive MH, Recordon-Pinson P, Ragnaud JM, Fleury H.
    Antivir Ther; 2006 Feb 05; 11(6):827-30. PubMed ID: 17310827
    [Abstract] [Full Text] [Related]

  • 13. K65R, TAMs and tenofovir.
    Miller MD.
    AIDS Rev; 2004 Feb 05; 6(1):22-33. PubMed ID: 15168738
    [Abstract] [Full Text] [Related]

  • 14. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
    Margot NA, Waters JM, Miller MD.
    Antimicrob Agents Chemother; 2006 Dec 05; 50(12):4087-95. PubMed ID: 16982781
    [Abstract] [Full Text] [Related]

  • 15. The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
    Li S, Ouyang J, Zhao B, An M, Wang L, Ding H, Zhang M, Han X.
    BMC Infect Dis; 2020 Feb 11; 20(1):123. PubMed ID: 32046664
    [Abstract] [Full Text] [Related]

  • 16. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
    Parikh UM, Bacheler L, Koontz D, Mellors JW.
    J Virol; 2006 May 11; 80(10):4971-7. PubMed ID: 16641288
    [Abstract] [Full Text] [Related]

  • 17. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
    Røge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J.
    Antivir Ther; 2003 Apr 11; 8(2):173-82. PubMed ID: 12741630
    [Abstract] [Full Text] [Related]

  • 18. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
    Miller MD, Haddad M, Su C, Gibbs C, McColl DJ, Guyer B.
    Antivir Ther; 2012 Apr 11; 17(6):993-9. PubMed ID: 22837442
    [Abstract] [Full Text] [Related]

  • 19. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW.
    Antimicrob Agents Chemother; 2007 Jan 11; 51(1):48-53. PubMed ID: 17088490
    [Abstract] [Full Text] [Related]

  • 20. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ, Chappey C, Parkin NT, Miller MD.
    Antivir Ther; 2008 Jan 11; 13(2):189-97. PubMed ID: 18505170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.